# Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

> **NCT01800695** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 202 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** ABT-414
- **DRUG:** Temozolomide
- **RADIATION:** Whole Brain Radiation

## Key facts

- **NCT ID:** NCT01800695
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-02
- **Primary completion:** 2017-06-19
- **Final completion:** 2017-06-19
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01800695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01800695, "Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01800695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*